InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（7 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
7
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Hickey Benjamin, 管理人员. Director active across 2 companies, notably Mirati Therapeutics, Inc.. Aggregated, 17 reports have been published. Split: 0 buy · 7 sells. Total volume traded: €647k. History available since 7 January 2022. The latest transaction was filed on 27 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Hickey Benjamin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
3,286 股0Common Stock, $0.10 par valueSEC:0001753055-26-000004:0
10,079 股0Common Stock, $0.10 par valueSEC:0001753055-26-000002:0
97.391 股@ US$38.01100.0% 占其流量Common Stock, $0.10 par valueSEC:0000014272-25-000097:0
3,286 股0Common Stock, $0.10 par valueSEC:0000014272-25-000045:0
10,078 股0Common Stock, $0.10 par valueSEC:0000014272-25-000014:0
27,801 股Common StockSEC:0001140361-24-003531:0
966 股@ US$59.022.1% 占其流量Common StockSEC:0001628280-24-001696:0
2,090 股@ US$58.924.4% 占其流量Common StockSEC:0001628280-24-000977:0
17,021 股@ US$58.7535.6% 占其流量Common StockSEC:0001628280-24-000290:0
2,220 股@ US$56.674.6% 占其流量Common StockSEC:0001628280-23-041610:0
22,297 股@ US$37.0029.6% 占其流量Common StockSEC:0001628280-23-028881:0
36,394 股0Common StockSEC:0001214659-23-001045:0
947 股@ US$42.37791.5% 占其流量Common StockSEC:0001214659-23-000808:0
2,088 股@ US$45.373.5% 占其流量Common StockSEC:0001214659-23-000466:0
19,149 股0Common StockSEC:0001214659-22-015199:0
10,755 股0Common StockSEC:0001214659-22-000855:0
1,964 股@ US$135.938910.3% 占其流量Common StockSEC:0001214659-22-000471:0
17 条申报中的 17 条
About Hickey Benjamin
Benjamin Hickey is an executive linked to Mirati Therapeutics, Inc. and Bristol Myers Squibb Co, with 17 filings in total. Across the 17 sampled filings, the period runs from 2022-01-07 to 2026-03-03, the dominant transaction type is a sale, and total sales amount to EUR 646715, including filings of EUR 903475.2854080361 on 2024-01-03 and EUR 751515.4981401361 on 2023-08-10 at Mirati Therapeutics, Inc.
